---
title: "GSK eyes future growth with cost-cutting plan amid promising Q2"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294228897.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-29T14:01:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294228897.md)
  - [en](https://longbridge.com/en/news/294228897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294228897.md)
generator: "portal-rs"
---

# GSK eyes future growth with cost-cutting plan amid promising Q2

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape](https://longbridge.com/en/news/299877282.md)
- [HUTCHMED launches first-in-human global trial of novel KRAS-EGFR cancer therapy HMPL-A830](https://longbridge.com/en/news/300234043.md)
- [GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro](https://longbridge.com/en/news/298875033.md)
- [GSK Presents Positive Data For Jideytro In First-Line Ros1-Positive NSCLC](https://longbridge.com/en/news/298874749.md)
- [Key facts: GSK Ris‑Rez halves death risk; Buys Chimagen trispecific](https://longbridge.com/en/news/299010934.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**